Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5969664 | 0.98 | HTR2C (0.32) | HTR2CHTR2BHTR2AHTR6L3MBTL3 | |
| SCHEMBL2265420 | 0.94 | HTR2C (0.33) | HTR2CHTR2BHTR2AMEN1ALDH1A1 | |
| SCHEMBL8491316 | 0.88 | HTR6 (0.41) | HTR6 | |
| SCHEMBL738778 | 0.84 | — | — | |
| SCHEMBL735596 | 0.82 | CTDSP1 (0.34) | HTR6 | |
| SCHEMBL6641164 | 0.82 | CTDSP1 (0.34) | HTR6 | |
| SCHEMBL738719 | 0.82 | CTDSP1 (0.34) | — | |
| SCHEMBL2553676 | 0.82 | HTR6 (0.38) | HTR2CHTR2BHTR6 | |
| SCHEMBL737622 | 0.80 | CTDSP1 (0.33) | HTR6MEN1KMT2A | |
| SCHEMBL2007704 | 0.80 | CTDSP1 (0.33) | HTR6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3122744-B1 | DIAZASPIROALKANEONE-SUBSTITUTED OXAZOLE DERIVATIVES AS SPLEEN TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2018-11-07 | — | — | EP | claimed |
| EP-2736904-B1 | OXAZOLE AND THIAZOLE DERIVATIVES AS SELECTIVE PROTEIN KINASE INHIBITORS (C-KIT) | AB SCIENCE (FR) | 2016-03-16 | — | — | EP | claimed |
| EP-1960372-B1 | KINASE INHIBITORS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2015-12-09 | — | — | EP | claimed |
| US-9168245-B2 | Selective protein kinase inhibitors | AB SCIENCE (FR) | 2015-10-27 | — | — | US | claimed |
| US-20140179698-A1 | SELECTIVE PROTEIN KINASE INHIBITORS | AB SCIENCE (FR) | 2014-06-26 | — | — | US | claimed |
| EP-2736904-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS SELECTIVE PROTEIN KINASE INHIBITORS (C-KIT) | AB Science (FR) | 2014-06-04 | — | — | EP | claimed |
| WO-2013014170-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS SELECTIVE PROTEIN KINASE INHIBITORS (C-KIT) | AB SCIENCE (FR) | 2013-01-31 | — | — | WO | claimed |
| US-8053434-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-11-08 | — | — | US | claimed |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | claimed |
| US-7601713-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | claimed |
| US-6593327-B2 | N-cyanomethyl amides which are cysteine protease inhibitors; treating osteoporosis; mixtures with bisphosphonates | AXYS PHARMACEUTICALS, INC. | 2003-07-15 | — | — | US | claimed |
| EP-3253749-B1 | COMPOUNDS WITH ANTI-TUMORAL ACTIVITY | AB SCIENCE (FR) | 2021-12-08 | — | — | EP | disclosed |
| EP-3350176-B1 | NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK | AB SCIENCE (FR) | 2021-04-28 | — | — | EP | disclosed |
| EP-3053920-B1 | COMPOUNDS WITH ANTI-TUMORAL ACTIVITY | AB SCIENCE (FR) | 2020-04-08 | — | — | EP | disclosed |
| US-10570122-B2 | Compounds with anti-tumoral activity | AB SCIENCE (FR) | 2020-02-25 | — | — | US | disclosed |
| US-6492362-B1 | Compounds and compositions as cathepsin S inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
| US-6476026-B1 | Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-11-05 | — | — | US | disclosed |
| US-20020156063-A1 | Arylacetamido-ketobenzoxazole as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-10-24 | — | — | US | disclosed |
| US-6455502-B1 | Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-09-24 | — | — | US | disclosed |
| US-20020086996-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156063-A1 | Arylacetamido-ketobenzoxazole as cysteine protease inhibitors | SERPINB1, SPINT2, PRSS1 | HTR2C 3831/4885HTR2B 3288/4885HTR2A 4206/4885 |
| US-20020086996-A1 | Novel compounds and compositions as protease inhibitors | CTRL, SERPINB1, CPN1 | HTR2C 4375/4885HTR2B 3966/4885HTR2A 4434/4885 |
| US-10570122-B2 | Compounds with anti-tumoral activity | MKI67, GZMB, RB1 | HTR2C 4546/4885HTR2B 3848/4885HTR2A 4541/4885 |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, JAK2 | HTR2C 3644/4885HTR2B 2379/4885HTR2A 3723/4885 |
| US-20140179698-A1 | SELECTIVE PROTEIN KINASE INHIBITORS | KIT, MAP3K1, PRKCH | HTR2C 2777/4885HTR2B 2346/4885HTR2A 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.